The History of Synephrine: How the Supplement Became Popular
Today synephrine can be found on the labels of hundreds of fat burners and pre-workout complexes. But this substance has a long and not entirely obvious history: from bitter orange fruit and a European medicine to the “successor” of banned ephedra. Our editorial team traced how synephrine became a mass-market supplement and why disputes around it continue to this day.
Bitter orange before the age of supplements
The history of synephrine begins long before sports stores — with the bitter orange, or Seville orange (Citrus aurantium). This plant has been used for centuries in cooking, perfumery, and folk medicine. The peel of the Seville orange is used to make classic orange marmalade, the flowers yield neroli essential oil, and the dried unripe fruits, under the name Zhi Shi, are part of traditional Chinese medicine as a digestive aid.
Of course, nothing was known then about the active alkaloids in these fruits. The plant was valued for its aroma, bitterness, and supposed tonic properties, not for a specific molecule. This path from traditional use to an isolated “active substance” is characteristic of many plant supplements.
It is important to understand that modern synephrine in supplements is almost always a standardized extract of unripe bitter orange fruit. Sweet oranges, mandarins, and other citrus fruits also contain synephrine, but in much smaller amounts, so people receive microdoses of it daily from citrus juices.
It was precisely this connection with familiar food that later became one of the arguments of synephrine’s proponents for its safety, while critics, on the contrary, emphasized that concentrated extracts deliver amounts unattainable with an ordinary diet.
From a synthetic drug to a natural alkaloid
As a separate substance, synephrine appeared in pharmacology in the first half of the 20th century. It was obtained synthetically and used in Europe as a vasoconstrictor and hypertensive agent under the trade name “Sympatol”; the substance’s international nonproprietary name is oxedrine. The drug was used, in particular, for low blood pressure.
Only later did chemists discover that the same molecule is naturally present in citrus fruits. Studies published in the 1960s described the presence of synephrine in the leaves and fruits of various species ofCitrus. Thus the synthetic medicine acquired a “natural” origin, which marketing would later actively exploit.
Chemically, synephrine is a phenylethylamine, close in structure to adrenaline, noradrenaline, octopamine, and ephedrine. This similarity explains both its pharmacological interest and the constant concerns of regulators. There are several isomers: in bitter orange para-synephrine dominates, while meta-synephrine is known as phenylephrine — an entirely different medicine.
This confusion of isomers played a notable role in the history: in early publications it was not always distinguished which form was meant, and data on the strong vascular effect of phenylephrine were sometimes mechanically transferred to para-synephrine. Later reviews, in particular the work of Stohs and colleagues, devoted much attention to this issue.
Ephedra, the 2004 ban, and the “ephedra-free” wave
The real boom in synephrine is connected with the fate of another plant — ephedra. In the 1990s, supplements with ephedra alkaloids and caffeine became very popular fat burners in the United States. At the same time, reports accumulated of serious cardiovascular and neurological complications, including strokes and deaths.
In 2004, the U.S. Food and Drug Administration (FDA) published a final rule that recognized dietary supplements with ephedra alkaloids as posing an unreasonable risk and effectively removed them from the market. Manufacturers faced the need to quickly find a replacement.
Bitter orange turned out to be a convenient candidate: plant origin, a history of food use, structural similarity of its main alkaloid to ephedrine. Thus appeared products labeled “ephedra-free,” where ephedra was replaced with an extractCitrus aurantium, often in combination with caffeine.
The review by Haaz and colleagues in 2006 summarized the evidence base of the time regarding weight loss and concluded that the data were insufficient for firm conclusions. However, the market developed faster than the science: synephrine became established as one of the most common components of thermogenics and pre-workout complexes.
Scientific disputes and the position of regulators
Popularity also brought close attention. Regulators in several countries assessed the safety of synephrine, especially in combination with caffeine. The German Federal Institute for Risk Assessment (BfR), in its opinion on sports products and weight-loss aids containing synephrine and caffeine, recommended caution regarding such combinations.
On the other hand, synephrine’s proponents, in particular the Stohs group, published reviews emphasizing that para-synephrine has a much weaker effect on the cardiovascular system than ephedrine, owing to its lower affinity for alpha- and beta-1/beta-2-adrenergic receptors. In a number of controlled studies, no noticeable changes in blood pressure or pulse were found at moderate amounts.
The problem is that in real products synephrine is rarely alone: it is combined with caffeine, yohimbine, and other stimulants. Reports of adverse events often concern precisely such mixtures, and it is difficult to separate the contribution of each component.
In sport, synephrine is not on the WADA Prohibited List, but it is on the Monitoring Program, through which the agency tracks the prevalence of substances among athletes. This underscores its “borderline” status.
| Period | Key event | Consequence for the market |
|---|---|---|
| Traditional stage | Use of bitter orange in food and folk medicine | The image of a “natural” plant |
| 20th century | Synthetic drug, later identification in citrus fruits | A pharmacological basis |
| 2004 | Ban on ephedra supplements in the U.S. | Mass switch to bitter orange |
| 2010s | Controlled studies of p-synephrine, regulators’ conclusions | Disputes over the safety of combinations |
What the history of synephrine teaches
The history of synephrine is a telling example of how regulatory decisions shape the supplement market. An ingredient often becomes popular not because of new evidence of efficacy, but because a spot opened up after a predecessor was banned.
The second lesson is the importance of precise chemistry. The confusion between para- and meta-synephrine, between synephrine and octopamine — which WADA classifies as a prohibited stimulant — caused many conflicting interpretations. For the consumer this means that a good label should indicate both the form and the standardization of the extract.
The third lesson concerns combinations. Most safety concerns are associated not with the individual substance, but with mixtures of stimulants. Modern studies, for example the work of Gutiérrez-Hellín and Del Coso on fat oxidation during exercise, try to study synephrine in isolation, but the market continues to sell it in “cocktails.”
Summarizing, the editorial team highlights the factors that made synephrine a mass-market supplement:
- a vacated market niche after the ephedra ban;
- plant origin and a connection with familiar citrus fruits;
- structural similarity to ephedrine, which facilitated marketing;
- the low cost of standardized extracts.
Finally, the history shows that “natural” does not equal “safe.” Plant origin does not cancel out pharmacological activity, and people with hypertension, heart disease, or those taking other stimulants or antidepressants should be especially cautious.
Editorial conclusions
Synephrine traveled the path from a component of a traditional plant, through a synthetic medicine, to one of the best-known ingredients in fat burners. The decisive impetus was the ban on ephedra in U.S. supplements in 2004.
The scientific discussion about its efficacy and safety continues: some controlled studies show moderate metabolic effects and acceptable tolerability, while regulators warn about combinations with stimulants.
For the reader the main takeaway is this: the popularity of synephrine is largely a market phenomenon rather than the result of convincing evidence, so expectations of it should be restrained.
Our articles “Synephrine During Cutting: Does It Help,” “Synephrine and Sleep,” and “How to Choose a Quality Synephrine: What to Look For on the Label” will help you continue the topic.
References
- Stohs SJ, Preuss HG, Shara M. A review of the human clinical studies involving Citrus aurantium (bitter orange) extract and its primary protoalkaloid p-synephrine. Int J Med Sci. 2012;9(7):527–538.
- Haaz S, Fontaine KR, Cutter G, et al. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7(1):79–88.
- U.S. Food and Drug Administration. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Fed Regist. 2004;69(28).
- Gutiérrez-Hellín J, Del Coso J. Acute p-synephrine ingestion increases fat oxidation rate during exercise. Br J Clin Pharmacol. 2016;82(2):362–368.
- Stohs SJ. Safety, efficacy, and mechanistic studies regarding Citrus aurantium (bitter orange) extract and p-synephrine. Phytother Res. 2017;31(10):1463–1474.
- Bundesinstitut für Risikobewertung (BfR). Health assessment of sports and weight loss products containing synephrine and caffeine. BfR Opinion. Berlin: BfR; 2012.
- World Anti-Doping Agency. The Monitoring Program. Montreal: WADA; чинна редакція.
Andriy Melnyk
A strength-sports coach and author of programs for beginner and intermediate levels. Writes about training planning.
